Melissa Addae Mensah, PMHNP-BC
Psychiatric/Mental Health · Long Beach
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Melissa Addae Mensah’s office at (562) 365-2020 to ask if they take your plan before you enroll.
Drugs they prescribed that Part D paid
$337
Pharmacies billed $337 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 54) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
54 generic and 0 brand-name prescriptions · $337 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Fluoxetine | 19 | $134 | $7 |
Money from drug and device companies
$1,157 in 2025
| 2025 | 7 | 35 | None | $1,157 |
| 2024 | 4 | 7 | None | $527 |
| 2023 | 1 | 2 | None | $129 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $383 | 10 payments
|
| Otsuka America Pharmaceutical | Rexulti | $302 | 10 payments
|
| Abbvie | Vraylar | $267 | 10 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $117 | 2 payments
|
| Vanda Pharmaceuticals | Fanapt | $36 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $30 | 1 payment
|
See all 35 published payments
| Otsuka America Pharmaceutical | Meals · 2025-11-21 | Rexulti | $12 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-11-21 | Caplyta | $26 |
| Abbvie | Meals · 2025-10-24 | Vraylar | $19 |
| Otsuka America Pharmaceutical | Meals · 2025-10-24 | Rexulti | $12 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-10-17 | Caplyta | $33 |
| Abbvie | Meals · 2025-10-03 | Vraylar | $7 |
| Collegium Pharmaceutical | Meals · 2025-10-02 | Jornay Pm | $23 |
| Abbvie | Meals · 2025-09-22 | Vraylar | $13 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-19 | Cobenfy | $30 |
| Otsuka America Pharmaceutical | Meals · 2025-09-04 | Rexulti | $125 |
| Otsuka America Pharmaceutical | Meals · 2025-08-29 | Rexulti | $10 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-08-22 | Caplyta | $26 |
| Vanda Pharmaceuticals | Meals · 2025-08-08 | Fanapt | $36 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-08-08 | Caplyta | $5 |
| Abbvie | Meals · 2025-08-07 | Vraylar | $96 |
| Janssen Pharmaceuticals | Meals · 2025-08-01 | Invega Sustenna | $36 |
| Otsuka America Pharmaceutical | Meals · 2025-08-01 | Rexulti | $8 |
| Abbvie | Meals · 2025-07-25 | Vraylar | $5 |
| Abbvie | Meals · 2025-07-18 | Vraylar | $20 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-06-27 | Caplyta | $6 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-06-13 | Caplyta | $27 |
| Otsuka America Pharmaceutical | Meals · 2025-05-30 | Rexulti | $9 |
| Abbvie | Meals · 2025-05-16 | Vraylar | $24 |
| Abbvie | Meals · 2025-05-14 | Vraylar | $33 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-04-23 | Caplyta | $99 |
| Janssen Pharmaceuticals | Meals · 2025-04-15 | Invega Sustenna | $81 |
| Otsuka America Pharmaceutical | Meals · 2025-04-11 | Rexulti | $8 |
| Abbvie | Meals · 2025-03-27 | Vraylar | $19 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-03-14 | Caplyta | $5 |
| Otsuka America Pharmaceutical | Meals · 2025-03-07 | Rexulti | $9 |
| Otsuka America Pharmaceutical | Meals · 2025-02-26 | Rexulti | $104 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-02-12 | Caplyta | $148 |
| Otsuka America Pharmaceutical | Meals · 2025-01-31 | Rexulti | $6 |
| Abbvie | Meals · 2025-01-24 | Vraylar | $31 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-01-24 | Caplyta | $8 |
See earlier years (2024, 2023)
2024: $527
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $156 | 4 payments
|
| Vanda Pharmaceuticals | Fanapt | $125 | 1 payment
|
| Teva Pharmaceuticals USA | Austedo Xr | $123 | 1 payment
|
| Abbvie | Vraylar | $123 | 1 payment
|
2023: $129
| Janssen Pharmaceuticals | Invega Sustenna | $129 | 2 payments
|
Professional record
- NPI
- 1568171668
- Licence
- CA 95000497
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LP0808X (363LP0808X)
- Mailing address
- 5199 E Pacific Coast Hwy Ste 330n, Long Beach, CA, 90804
- NPI first listed
- 2022-11-16
- NPI last updated
- 2023-08-11
- NPI record certified
- 2023-08-11
This is when the NPI record was last certified, not a medical board exam.